The Btk tyrosine kinase is a major target of the Bcr-Abl inhibitor dasatinib

Dasatinib is a small-molecule kinase inhibitor used for the treatment of imatinib-resistant chronic myelogenous leukemia (CML). We have analyzed the kinases targeted by dasatinib by using an unbiased chemical proteomics approach to detect binding proteins directly from lysates of CML cells. Besides Abl and Src kinases, we have identified the Tec kinases Btk and Tec, but not Itk, as major binders of dasatinib. The kinase activity of Btk and Tec, but not of Itk, was inhibited by nanomolar concentrations of dasatinib in vitro and in cultured cells. We identified the gatekeeper residue as the critical determinant of dasatinib susceptibility. Mutation of Thr-474 in Btk to Ile and Thr-442 in Tec to Ile conferred resistance to dasatinib, whereas mutation of the corresponding residue in Itk (Phe-435) to Thr sensitized the otherwise insensitive Itk to dasatinib. The configuration of this residue may be a predictor for dasatinib sensitivity across the kinome. Analysis of mast cells derived from Btk-deficient mice suggested that inhibition of Btk by dasatinib may be responsible for the observed reduction in histamine release upon dasatinib treatment. Furthermore, dasatinib inhibited histamine release in primary human basophils and secretion of proinflammatory cytokines in immune cells. The observed inhibition of Tec kinases by dasatinib predicts immunosuppressive (side) effects of this drug and may offer therapeutic opportunities for inflammatory and immunological disorders.

[1]  J. Radich,et al.  Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia after failure of first-line imatinib: a randomized phase 2 trial. , 2007, Blood.

[2]  L. Meijer,et al.  Identification of intracellular targets of small molecular weight chemical compounds using affinity chromatography , 2007, Biotechnology journal.

[3]  Francisco Cervantes,et al.  Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. , 2006, The New England journal of medicine.

[4]  Susan O'Brien,et al.  Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. , 2006, The New England journal of medicine.

[5]  M. Wittekind,et al.  The structure of Dasatinib (BMS-354825) bound to activated ABL kinase domain elucidates its inhibitory activity against imatinib-resistant ABL mutants. , 2006, Cancer research.

[6]  B. Druker,et al.  Targeted CML therapy: controlling drug resistance, seeking cure. , 2006, Current opinion in genetics & development.

[7]  H. Daub.  Characterisation of kinase-selective inhibitors by chemical proteomics. , 2005, Biochimica et biophysica acta.

[8]  M. Baccarani,et al.  Dual tyrosine kinase inhibitors in chronic myeloid leukemia , 2005, Leukemia.

[9]  William Pao,et al.  Inhibition of drug-resistant mutants of ABL, KIT, and EGF receptor kinases. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[10]  J. Rowley,et al.  Mimicry of a constitutively active pre–B cell receptor in acute lymphoblastic leukemia cells , 2005, The Journal of experimental medicine.

[11]  J. Mestan,et al.  In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants. , 2005, Cancer research.

[12]  L. Wodicka,et al.  A small molecule–kinase interaction map for clinical kinase inhibitors , 2005, Nature Biotechnology.

[13]  Donna Neuberg,et al.  Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl. , 2005, Cancer cell.

[14]  Ping Chen,et al.  Discovery of N-(2-chloro-6-methyl- phenyl)-2-(6-(4-(2-hydroxyethyl)- piperazin-1-yl)-2-methylpyrimidin-4- ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays. , 2004, Journal of medicinal chemistry.

[15]  M. Cotten,et al.  Chemical Proteomic Analysis Reveals Alternative Modes of Action for Pyrido[2,3-d]pyrimidine Kinase Inhibitors* , 2004, Molecular & Cellular Proteomics.

[16]  K. Wilson,et al.  Structural Basis for the Autoinhibition and STI-571 Inhibition of c-Kit Tyrosine Kinase* , 2004, Journal of Biological Chemistry.

[17]  Ping Chen,et al.  Overriding Imatinib Resistance with a Novel ABL Kinase Inhibitor , 2004, Science.

[18]  L. Burdine,et al.  Target identification in chemical genetics: the (often) missing link. , 2004, Chemistry & biology.

[19]  G. Cheetham,et al.  Crystal Structures of Interleukin-2 Tyrosine Kinase and Their Implications for the Design of Selective Inhibitors* , 2004, Journal of Biological Chemistry.

[20]  O. Witte,et al.  The BCR-ABL story: bench to bedside and back. , 2004, Annual review of immunology.

[21]  H. Mano,et al.  Bruton's Tyrosine Kinase Is Required For Lipopolysaccharide-induced Tumor Necrosis Factor α Production , 2003, The Journal of experimental medicine.

[22]  G. Superti-Furga,et al.  Structural Basis for the Autoinhibition of c-Abl Tyrosine Kinase , 2003, Cell.

[23]  J. Kuriyan,et al.  Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. , 2002, Cancer cell.

[24]  F. Uckun,et al.  Crystal Structure of Bruton's Tyrosine Kinase Domain Suggests a Novel Pathway for Activation and Provides Insights into the Molecular Basis of X-linked Agammaglobulinemia* , 2001, The Journal of Biological Chemistry.

[25]  P. Schwartzberg,et al.  Tec kinases: modulators of lymphocyte signaling and development. , 2001, Current opinion in immunology.

[26]  M. Vihinen,et al.  The Tec family of cytoplasmic tyrosine kinases: mammalian Btk, Bmx, Itk, Tec, Txk and homologs in other species , 2001, BioEssays : news and reviews in molecular, cellular and developmental biology.

[27]  John Kuriyan,et al.  Crystal structures of the kinase domain of c-Abl in complex with the small molecule inhibitors PD173955 and imatinib (STI-571). , 2001, Cancer research.

[28]  M. Vihinen,et al.  Bruton tyrosine kinase (BTK) in X-linked agammaglobulinemia (XLA). , 2000, Frontiers in bioscience : a journal and virtual library.

[29]  P. Seeburg,et al.  Structural mechanism for STI-571 inhibition of abelson tyrosine kinase. , 2000, Science.

[30]  A. Satterthwaite,et al.  Redundant and Opposing Functions of Two Tyrosine Kinases, Btk and Lyn, in Mast Cell Activation1 , 2000, The Journal of Immunology.

[31]  F. Alt,et al.  Involvement of Bruton's Tyrosine Kinase in FcεRI-dependent Mast Cell Degranulation and Cytokine Production , 1998, The Journal of experimental medicine.

[32]  D J Rawlings,et al.  Regulation of Btk function by a major autophosphorylation site within the SH3 domain. , 1996, Immunity.

[33]  Charis Eng,et al.  Catalytic specificity of protein-tyrosine kinases is critical for selective signalling , 1995, Nature.

[34]  B. Druker,et al.  Oncogenes and Tumor Suppressors (795 articles) , 2004 .

[35]  Oliver Hantschel,et al.  Regulation of the c-Abl and Bcr–Abl tyrosine kinases , 2004, Nature Reviews Molecular Cell Biology.

[36]  M. Vihinen,et al.  BTK, the tyrosine kinase affected in X-linked agammaglobulinemia. , 1997, Frontiers in bioscience : a journal and virtual library.

[37]  T. Meyer,et al.  Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative. , 1996, Cancer research.